EG 427 announces final Series A closing, achieving €18 million in total funds raised
"EG110A is the first genuinely innovative approach to be developed for patients suffering neurogenic bladder overactivity in more than a decade"
26-Jul-2023 -
EG 427, a biotechnology company leading the development of pinpoint DNA medicine solutions, announces the final closing of a Series A financing. EG 427 raised an additional €5 million in the final closing from a combination of existing investors and new family office investors, bringing the total ...
gene therapies
Series A financing